# Medicure Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Medicure Inc).

## Overview

Medicure Inc. is a U.S.-focused pharmaceutical company that develops and commercializes prescription medicines and related healthcare products. Its business combines branded drug marketing with pharmacy operations through subsidiaries that serve patients, prescribers, long-term care facilities, and retail customers in the United States.

## Products & services

• AGGRASTAT® (tirofiban hydrochloride) injection
• ZYPITAMAG® (pitavastatin) tablets
• Pharmacy dispensing and home delivery
• Compounding services for pharmacy patients
• Long-term care pharmacy services

- **Branded pharmaceuticals** (45%) — Prescription medicines marketed and distributed in the U.S., including AGGRASTAT® and ZYPITAMAG®.
- **Retail pharmacy services** (35%) — Prescription fulfillment, dispensing, and free home delivery through Marley Drug.
- **Specialty and long-term care pharmacy** (15%) — Pharmacy services for institutional and long-term care customers, including medication management.
- **Compounding services** (5%) — Non-sterile compounding services provided through select pharmacy locations.

- AGGRASTAT® (tirofiban hydrochloride) injection
- ZYPITAMAG® (pitavastatin) tablets
- Pharmacy dispensing and home delivery
- Compounding services for pharmacy patients
- Long-term care pharmacy services

## Customers

Medicure sells mainly to U.S. patients, prescribers, pharmacies, and healthcare organizations that need prescription medicines and dispensing services. Its branded drug business serves physicians and patients in cardiovascular and lipid-management treatment areas, while its pharmacy businesses serve retail customers, long-term care facilities, and patients needing delivery or compounding support.

- **Physicians and prescribing clinicians** (primary) — Prescribers who choose AGGRASTAT® and ZYPITAMAG® for patients based on clinical need.
- **Retail prescription patients** (primary) — Patients filling prescriptions through Marley Drug for convenience and access.
- **Long-term care facilities** (secondary) — Facilities buying pharmacy services and medication support for residents.
- **Patients needing home delivery** (secondary) — Customers using free delivery to receive medications directly at home.
- **Compounding patients** (emerging) — Patients requiring non-sterile compounded medications from pharmacy locations.

- Patients filling prescriptions in the United States
- Prescribers using AGGRASTAT® and ZYPITAMAG®
- Retail customers served by Marley Drug
- Long-term care facilities needing pharmacy support
- Patients needing home delivery or compounding

## Geography

Medicure’s business is centered in the United States, where its pharmaceuticals are marketed and its pharmacy operations serve all 50 states, Washington D.C., and Puerto Rico. The company also operates pharmacy locations in Portland, Oregon and Olympia, Washington, giving it a physical presence tied to local clinic and transportation networks.

- **United States** (100%) — Company describes all commercial focus in the U.S. market.

- U.S. is the core market for both drugs and pharmacy services
- Marley Drug serves all 50 states, Washington D.C., and Puerto Rico
- Gateway Medical Pharmacy operates in Portland, Oregon
- West Olympia Pharmacy operates in Olympia, Washington
- U.S. healthcare regulation and reimbursement are key demand drivers

## Strategy

Medicure’s strategy centers on sustaining its branded pharmaceutical portfolio while using pharmacy subsidiaries to broaden access to medications and build recurring customer relationships. The company also uses local pharmacy locations and delivery capabilities to support patient access, institutional accounts, and service differentiation.

- **Commercialize branded medicines in the U.S.** (short-term) — The branded drug portfolio is the core product base and drives physician and patient demand.
- **Expand pharmacy access and retention** (medium-term) — Delivery and local pharmacy services increase customer convenience and repeat prescriptions.
- **Support institutional pharmacy relationships** (medium-term) — Long-term care accounts can provide recurring prescription volume and service depth.

- Defend and market AGGRASTAT® and ZYPITAMAG® in the U.S.
- Use pharmacy operations to expand access and repeat business
- Serve both retail and institutional pharmacy demand
- Leverage free home delivery as a customer-retention tool
- Maintain a focused U.S. commercial footprint

## Risks

Medicure depends on a small set of prescription products and pharmacy operations, so concentration, competition, and reimbursement pressure can materially affect results. The company also faces regulatory, inventory, and estimation risks common to pharmaceutical and pharmacy businesses, including returns, chargebacks, rebates, and fair-value assumptions on obligations and contingent items.

- **Product concentration** [high] — The company’s commercial focus is centered on AGGRASTAT® and ZYPITAMAG®.
- **Reimbursement and pricing pressure** [high] — Pharmacy and prescription drug businesses depend on payer and market pricing dynamics.
- **Regulatory compliance** [high] — Prescription drugs and pharmacy operations are subject to healthcare and dispensing regulation.
- **Revenue reserve estimates** [medium] — Returns, chargebacks, rebates, and discounts require ongoing accrual estimates.
- **Fair value and royalty assumptions** [medium] — Royalty obligations and contingent items depend on valuation inputs and future revenue assumptions.

- Dependence on a small product set increases concentration risk
- Pharmacy reimbursement and pricing pressure can affect demand
- Regulatory and compliance requirements are material in pharma
- Returns, rebates, and chargebacks require significant estimates
- Fair value judgments affect royalty and contingent liability balances

## Accounting

Medicure’s financial statements rely on judgment in areas that directly affect reported earnings and balance-sheet values. Key estimates include accruals for returns, chargebacks, rebates and discounts, as well as fair-value and amortized-cost measurements for royalty obligations, contingent consideration, and other liabilities.

- **Revenue reserve accruals** — Branded pharmaceutical net sales
- **Royalty obligation valuation** — Balance sheet liability and finance expense
- **Contingent consideration fair value** — Earnings volatility
- **Fair value investment accounting** — Comprehensive income and assets
- **Interim reporting estimates** — Quarterly comparability

- Accruals for returns, chargebacks, rebates, and discounts
- Fair value of royalty obligations and contingent consideration
- Estimated future AGGRASTAT® sales in liability valuation
- Investment in Sensible Medical measured at fair value
- IAS 34 interim reporting affects quarterly comparability

---

*Last updated: 2026-09-28T12:04:23.888194+00:00*